Skip to main content
. 2021 Sep 18;10(9):2475. doi: 10.3390/cells10092475

Figure 6.

Figure 6

The effects of administering rapamycin-preconditioned ADSCs on liver TGF-β1/Smad signaling pathway in cisplatin (Cis)-induced liver damage. (A) TGF-β1 relative mRNA expression in the study groups. (B) Smad3 relative mRNA expression in the study groups. (C) Smad7 relative mRNA expression in the study groups. (D) Immunohistochemical staining of TGF-β1 in the liver tissue in the different groups, magnification 400×. (E) TGF-β1 score from the images in (D) from the different studied groups. Cis, cisplatin (i.p. injection of 5 mg/kg in 0.9% saline) group; Cis + ADSCs, cisplatin group receiving ADSCs (one million cells, intravenous in tail vein); Cis + Rapa-ADSCs, cisplatin group receiving same number of ADSCs preconditioned with rapamycin (50 nM/L, 2 h prior to administration). Statistical significance, * vs. control group (p < 0.01), # vs. Cis group (p < 0.01) and $ vs. Cis+ADSCs group (p < 0.05).